Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Abstract : In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.
Liste complète des métadonnées
Contributeur : Lilloa Université de Lille Connectez-vous pour contacter le contributeur
Soumis le : lundi 15 février 2021 - 09:55:18
Dernière modification le : jeudi 25 novembre 2021 - 16:26:04
Archivage à long terme le : : dimanche 16 mai 2021 - 18:33:11


2020_Solé_Rev Neurol.pdf
Fichiers produits par l'(les) auteur(s)



G Solé, E Salort-Campana, Y Pereon, T Stojkovic, K Wahbi, et al.. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.. Revue Neurologique, Elsevier Masson, 2020, Revue Neurologique, 176 (6), pp.507-515. ⟨10.1016/j.neurol.2020.04.004⟩. ⟨hal-03141170⟩



Consultations de la notice


Téléchargements de fichiers